Sublingual allergen immunotherapy in immunosuppressed rheumatoid arthritis patients: Safety and clinical outcomes

Le résumé fourni par la source

Background: Allergen immunotherapy (AIT) is an effective disease-modifying treatment for allergic rhinitis. However, autoimmune diseases such as rheumatoid arthritis (RA) are traditionally considered relative contraindications, and evidence on the safety and efficacy of AIT in patients receiving immunosuppressive therapy remains limited. Objective: We assessed the clinical efficacy, safety, and immunologic effects of sublingual immunotherapy (SLIT) for Japanese cedar pollen (JCP)-induced allergic rhinitis in patients with RA well controlled by stable immunosuppressive treatment. Methods: levels were measured every 3 months. Pollen counts were monitored using the Durham method at a regional environmental monitoring site. Results: consistent with SLIT exposure. Conclusion: In this small cohort, SLIT for JCP was well tolerated and associated with potential clinical and immunologic benefits in patients with stable RA receiving immunosuppressive therapy. These findings support the possibility that AIT may be feasible in selected patients with autoimmune diseases.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.